Orally Administrable Aggregation‐Induced Emission‐Based Bionic Probe for Imaging and Ameliorating Dextran Sulfate Sodium‐Induced Inflammatory Bowel Diseases
Advanced Healthcare Materials · 2023
DOI: 10.1002/adhm.202202420 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2023. Verfasst von Wenyuan Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Colitis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
As macrophage infiltration is significantly related to the progression of inflammatory bowel disease (IBD), monitoring the macrophages is a valuable strategy for IBD diagnosis. However, owing to the harsh physiological environment of the gastrointestinal tract and enzymatic degradation, the development of orally administrable imaging probes for tracking macrophages remains a considerable challenge. Accordingly, herein, an orally administrable aggregation‐induced emission biomimetic probe (HBTTPIP/ β ‐glucan particles [GPs]) is developed for tracing macrophages; HBTTPIP/GPs can diagnose and alleviate dextran sulfate sodium (DSS)‐induced colonic inflammation and self‐report the treatment efficiency. The fluorophore HBTTPIP can effectively aggregate in GPs, restricting intramolecular rotation and activating the fluorescence of HBTTPIP. After being orally administrated, HBTTPIP/GPs are phagocytosed by intestinal macrophages, which then migrate to colonic lesions, enabling non‐invasive monitoring of the severity of IBD via in vivo fluorescence imaging. Notably, oral HBTTPIP/GPs ameliorate DSS‐induced IBD by inhibiting the expressions of pro‐inflammatory factors and improving colonic mucosal barrier function. Furthermore, these HBTTPIP/GPs realize self‐feedback of the therapeutic effects of GPs on DSS‐induced colitis. The oral biomimetic probe HBTTPIP/GPs reported herein provide a novel theranostic platform for IBD, integrating non‐invasive diagnosis of IBD in situ and the corresponding treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
- Hubei Province Clinical Research Center for Medical Imaging, Wuhan, 430022, China.
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China.
- Metabolic Vascular Disease Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
- Department of Vascular Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
ORCID-Profile: Mingxing Xie
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, W., Wu, Y., Wang, Y., Wang, R., Deng, C., Yi, L., Wang, L., He, M., Zhou, W., Xie, Y., Jin, Q., Chen, Y., Gao, T., Zhang, L., & Xie, M. (2023). Orally Administrable Aggregation‐Induced Emission‐Based Bionic Probe for Imaging and Ameliorating Dextran Sulfate Sodium‐Induced Inflammatory Bowel Diseases. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202202420
Vancouver
Wang W, Wu Y, Wang Y, Wang R, Deng C, Yi L, et al. Orally Administrable Aggregation‐Induced Emission‐Based Bionic Probe for Imaging and Ameliorating Dextran Sulfate Sodium‐Induced Inflammatory Bowel Diseases. Advanced Healthcare Materials. 2023. doi:10.1002/adhm.202202420
BibTeX
@article{Wang2023,
author = {Wang, Wenyuan and Wu, Ya and Wang, Yihui and Wang, Rui and Deng, Cheng and Yi, Luyang and Wang, Lufang and He, Mengrong and Zhou, Wuqi and Xie, Yuji and Jin, Qiaofeng and Chen, Yihan and Gao, Tang and Zhang, Li and Xie, Mingxing},
title = {Orally Administrable Aggregation‐Induced Emission‐Based Bionic Probe for Imaging and Ameliorating Dextran Sulfate Sodium‐Induced Inflammatory Bowel Diseases},
journal = {Advanced Healthcare Materials},
year = {2023},
doi = {10.1002/adhm.202202420}
}
EUVIMED